Voluma: A Systematic Review of Clinical Experience.
BACKGROUND
Dermal fillers are important for facial aesthetic enhancement as patients are favoring non-surgical procedures with minimal recovery time. Voluma is a volumizing hyaluronic acid filler, 20 mg/ml HA dermal filler, which was FDA-approved in 2013 as the first dermal filler for treatment of age-related volume loss in the midface.


OBJECTIVE
We sought to systematically review clinical studies and expert opinions of this 20 mg/ml HA dermal filler and to provide evidence-based recommendations and expert opinions.


METHODS
A search of the computerized bibliographic databases Medline, Embase, Embal, Biosis, SciSearch, Pascal, HCAPlus, IPA, and Dissertation Abstracts was performed on August 18th 2014.


RESULTS
Thirteen articles met inclusion and were included in our review: clinical trials with this 20 mg/ml HA dermal filler (10) and expert opinions and questionnaire survey studies of experts (3). This 20 mg/ml HA dermal filler has shown consistent, favorable results for treatment of age-related facial volume loss, aesthetic enhancement, and HIV facial lipoatrophy.


CONCLUSIONS
HA fillers are safe and effective with minimal recovery time and complications. Future studies with longer follow-up period and use of this 20 mg/ml HA dermal filler on areas other than midface may provide additional efficacy and safety outcomes.
Derek
D
Ho
Jared
J
Jagdeo
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000273:Adipose Tissue / Q000473:pathology*; D001284:Atrophy / Q000188:drug therapy / Q000821:virology; D000067548:Dermal Fillers / Q000009:adverse effects / Q000627:therapeutic use*; D004954:Esthetics; D055416:Evidence-Based Emergency Medicine; D005145:Face; D006801:Humans; D006820:Hyaluronic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D015595:Skin Aging / Q000187:drug effects*
D000067548:Dermal Fillers; D006820:Hyaluronic Acid